Table 2.
Final recommendations.
| Conditioning regimen | Stem cell source | Donor | Recommendation | Agreement among experts |
|---|---|---|---|---|
| MALIGNANT DISEASES | ||||
| Myeloablative | Bone marrow/peripheral blood | Unrelated | Recommended | Full |
| Myeloablative | Peripheral blood | HLA-identical sibling | Recommended | Partial |
| RIC/NMA | Bone marrow/peripheral blood | HLA-identical sibling/matched or mismatched unrelated | Partially recommended | Partial |
| Any conditioning plus post-transplant cyclophosphamide | Bone marrow/peripheral blood | Haploidentical | Undecidable | Full |
| Any conditioning without post-transplant cyclophosphamide) | Bone marrow/peripheral blood | Haploidentical | Advised to follow the conditioning published protocols | Full |
| Any conditioning | Cord blood transplant | Cord blood | Undecidable | Full |
| NON-MALIGNANT DISEASES | ||||
| Any conditioning | Any stem cell source | Recommended | Full | |
RIC reduced intensity conditioning, NMA nonmyeloablative conditioning.